Front Row with BioCentury: The Rapid Rise of Base Editing
With nearly two dozen base editors in the clinic, the nascent technology’s potential is coming into focus
Base editing is emerging as one of the most dynamic frontiers in genetic medicine, rapidly expanding from a handful of early programs to over 20 clinical candidates in just two years as the technology matures. In this episode of Front Row with BioCentury, Senior Biopharma Analyst Danielle Golovin breaks down the forces driving this surge — from advances in delivery and editor precision to the broadening range of therapeutic strategies now possible with single-base edits.
Golovin connects trends across the field, exploring why companies are increasingly turning to base editing for both in vivo and ex vivo approaches, how improved engineering is elevating the modality’s safety and efficiency, and where next-generation editors could push the boundaries of genomic medicine. ...